Antibody Technology Companies 2010 - A systematic guide through the landscape of antibody technologies and their providers

Date: November 22, 2010
Pages: 283
Price:
US$ 1,394.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AAD6C5CD494EN
Leaflet:

Download PDF Leaflet

Antibody Technology Companies 2010 -  A systematic guide through the landscape of antibody technologies and their providers
The report “Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers” provides a description and assessment of antibody technologies and their corporate providers as of November 2010. The report describes and analyzes the market size of therapeutic monoclonal antibodies and Fc-fusion proteins in 2009. Characteristics of approved antibody-based products regarding identification, construction and manufacturing are evaluated as a basis for relevant antibody technologies in 2010. Systematic profiles of 96 companies engaged in antibody technologies serve as the basis to present in a structured manner four clusters of platform technologies (generation, optimization, novel constructs, expression/manufacturing). The report serves as a systematic guide through the landscape of companies with antibody technologies for those in search of service providers or partners for collaboration or licensing.

Background

As of October 2010, 34 original therapeutic monoclonal antibodies and Fc-fusion proteins are marketed with 2009 sales exceeding US$ 45.4 bln. Thus, antibodies as a therapeutic modality and technology have matured and availability of new technologies as well as patent expirations offer a multitude of new options when designing an antibody-based product. While the established providers of transgenic mice have been acquired by Big Pharma/Biotech, a plethora of new antibody technologies appeared. Although this landscape of technologies for antibody lead generation and optimization, creation of combinatorial biologics and for expression/manufacturing offers an unprecedented range of possibilities, the selection of the most robust and adequate technologies fitting fitting to the product target profile has become more difficult than ever.

Scope of the report
  • Antibody market 2009
  • Technology analysis of 37 approved therapeutic antibody-based products
  • Profiles of 96 antibody technology companies
  • Antibody technology assessment
  • Antibody pipelines of technology companies
  • Overview of landscape of antibody technologies
  • Guide to identify suitable technologies and providers

Index
  • Overview
  • Market Size of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009
  • Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins
  • Platform Technologies for the Generation of Novel Therapeutic Antibody-based Products
  • Platform Technologies for the Optimization of Novel Therapeutic Antibody-based Products
  • Platform Technologies for Products beyond Monoclonal Antibodies
  • Platform Technologies for the Expression and Manufacturing of Novel Therapeutic Antibodies and Antibody-based Products
1 OVERVIEW

2 MARKET SIZE OF THERAPEUTIC MONOCLONAL ANTIBODIES AND FC-FUSION PROTEINS IN 2009

3 CHARACTERISTICS OF APPROVED THERAPEUTIC MONOCLONAL ANTIBODIES AND FC-FUSION PROTEINS16

4 PLATFORM TECHNOLOGIES FOR THE GENERATION OF NOVEL THERAPEUTIC ANTIBODYBASED PRODUCTS

4.1 In vivo generation of antibodies
4.2 In vitro generation of antibodies
4.3 Outlook

5 PLATFORM TECHNOLOGIES FOR THE OPTIMIZATION OF NOVEL THERAPEUTIC ANTIBODYBASED PRODUCTS

5.1 Use of natural immunoglobulin variants
5.2 Mutated immunoglobulins
5.3 Glcyo-engineering
5.4 Improvement of pharmaceutical quality
5.5 Outlook

6 PLATFORM TECHNOLOGIES FOR PRODUCTS BEYOND MONOCLONAL ANTIBODIES

6.1 Oligoclonal antibodies
6.2 Engineering of novel antibody-based products
6.3 Outlook

7 PLATFORM TECHNOLOGIES FOR THE EXPRESSION AND MANUFACTURING OF NOVEL THERAPEUTIC ANTIBODIES AND ANTIBODY-BASED PRODUCTS

7.1 Mammalian cells
7.2 Other eukaryotic systems
7.3 Yeast expression
7.4 Bacterial expression
7.5 Outlook

TABLES

Table 1: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 with Source of Information
Table 2: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Product
Table 3: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Therapeutic Area
Table 4: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Target
Table 5: Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins
Table 6: Generation of Monoclonal Antibodies in vivo
Table 7: Generation of Monoclonal Antibodies by B-cell Isolation
Table 8: Generation of Monoclonal Antibodies in vitro
Table 9: Generation of Monoclonal Antibodies in Cells in vitro
Table 10: Modification of Monoclonal Antibodies for Function – Protein and Glyco-Engineering
Table 11: Improvement of Pharmaceutial Quality of Antibodies
Table 12: Oligo- and Polyclonal Antibodies
Table 13: Novel Antibody-derived Formats by Protein Engineering
Table 14: Chemical and Protein Conjugates of Antibodies
Table 15: Automation of Antibody Lead Identification and Optimization
Table 16: Antibody: Druggability, Cross-Reactivity, Target Discovery and Others
Table 17: Expression and Manufacturing of Monoclonal Antibodies

FIGURES

Figure 1 Evolution of the Productivity of Mammalian Cell Culture
Figure 2 Calculation of Cost Structure for a Mammalian Cell Culture Process of a Recombinant Monoclonal Antibody – part I
Figure 3 Calculation of Cost Structure for a Mammalian Cell Culture Process of a Recombinant Monoclonal Antibody – part II

ADDENDUM

COMPANY PROFILES

4-Antibody
Abcheck
Abeome
Ablexis
Ablynx
AdAlta
Adimab
Affimed Therapeutics
Affitech
Alder Biopharmaceuticals
Alligator Biosciences
Ambrx
AnaptysBio
Antitope
arGEN-X
Armagen Technologies
Avanir Pharmaceuticals
Avipep
BioAtla
BioInvent
Biolex Therapeutics
Biosite
Biotecnol
Bristol-Myers Squibb (Medarex)
Calmune
Cephalon (Arana Therapeutics)
Chiome Bioscience
Crescendo Biologics
CytomX
Cytos
Discerna
Dyax
Elusys Therapeutics
Emergent Biosolutions (Trubion Pharmaceuticals)
Epitomics & Apexigen
Epivax
Esbatech & Delenex
Evec
ExcelImmune
f-star
Ganymed Pharmaceuticals
Genexine
Genmab
GlaxoSmithKline (Domantis)
Glycotope
GTC Biotherapeutics
Immunocellular Therapeutics
Immunogen
InNexus
InterVexion Therapeutics
Johnson & Johnson (Crucell)
Kalo Bios
Kenta Biotech
Kolltan
Kyowa Hakko Kirin (BioWa)
Lonza
MabCure
Macrogenics
MAT Biopharma
Merck & Co (GlycoFi)
Merrimack Pharmaceuticals
Merus
Micromet
Millegen
Morphosys
Morphotek
MSM Protein Technologies
Nascent Biologics
Neurimmune
North Coast Biologics
Open Monoclonal Technology (OMT)
OriGene Technologies
Oxford Biotherapeutics
Patrys
Pepscan Therapeutics
Pfizer (CovX)
Philogen
Planet Biotechnology
Regeneron
Sea Lane Biotechnologies
Seattle Genetics
Sloning Biotechnology
Sorrento Therapeutics
Symphogen
Synageva
Syntarga
Theraclone
Trellis
TRION Pharma
Vaccinex
Vivalis
Viventia Biotechnologies
XBiotech
Xencor
XOMA
Xori
Skip to top


Ask Your Question

Antibody Technology Companies 2010 - A systematic guide through the landscape of antibody technologies and their providers
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: